Fredericksen, R. J. http://orcid.org/0000-0003-3936-7048
Mixson, L. S.
Drumright, L. N.
Nance, R. M.
Delaney, J. A. C.
Ruderman, S. A.
Whitney, B. M.
Hahn, A.
Ma, J.
Mayer, K. H.
Christopoulos, K. A.
Willig, A. L.
Napravnik, S.
Bamford, L.
Cachay, E.
Eron, J. J.
Saag, M.
Jacobson, J.
Kitahata, M. M.
Crane, H. M.
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R24 AI067039, P30 AI027757, AI027767)
National Institute of Drug Abuse (R01DA047045)
Agency for Healthcare Research and Quality (U18HS026154)
Intramural Research Program, National Institute on Drug Abuse (R01DA058938, U24DA058307)
Article History
Accepted: 29 May 2024
First Online: 16 July 2024
Declarations
:
: K. Christopoulos has been a medical advisory board member for Gilead and a workshop participant for Janssen. J. Eron declares research funding from Gilead Sciences and ViiV Healthcare University of North Carolina-Chapel Hill as an investigator, and consulting fees paid to him from Merck & Co, ViiV Healthcare and Gilead Sciences. All other authors declare no conflicts of interest.